• InnoCare’s ICP-248 completes the first subject administration in clinical trail

    On March 10th, 2023, Beijing InnoCare announced that its independently developed BCL2 inhibitor ICP-248 completed the first subject administration in China. ICP-248 is a new oral highly selective BCL2 inhibitor independently developed by InnoCare. It is intended for the treatment of malignant hematological tumors such as non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic leukemia (ALL) as a monotherapy or in combination with other drugs such as BTK inhibitors. ICP-248 is currently being investigated for B-cell malignancies, malignant hematologic tumors, and hematologic tumors. BCL2 is an oncogene with a significant role in…